Today: 17 May 2026
Kongsberg Gruppen ASA stock price jumps 14% as Q4 backlog hits record and €140m weapons order lands
6 February 2026
1 min read

Kongsberg Gruppen ASA stock price jumps 14% as Q4 backlog hits record and €140m weapons order lands

Oslo, February 6, 2026, 13:04 CET — Regular session

  • Kongsberg shares surged about 14% after the company released its quarterly results and announced a new weapons contract
  • Company reports record order backlog and hints at a higher dividend for 2025
  • Investors are focusing on the April dividend dates as well as the group’s planned corporate split set for later this spring

Kongsberg Gruppen ASA (KOG.OL) shares surged 14% to 367.15 Norwegian crowns by 13:04 CET on Friday, recovering sharply after a 2.6% drop the day before.

European defence shares took the lead while broader stocks found their footing, buoyed by Kongsberg’s jump after reporting quarterly earnings and securing a $165 million weapons deal.

A stock exchange notice set the dividend timetable: a regular 2.20 crowns per share, alongside a special 3.50 crowns dividend. Both await approval on April 13. Shares go ex-dividend April 14, with payments due April 22.

Kongsberg posted a 21% rise in Q4 revenues to 16,776 million crowns. EBIT climbed to 2,464 million, lifting the EBIT margin to 14.7%. The order backlog hit 157,419 million crowns, with a book-to-bill ratio above 1 across all segments, signaling that new orders exceeded sales. The company also confirmed plans to spin off Kongsberg Maritime, targeting a separate listing on April 23, pending shareholder approval at the January extraordinary meeting.

Kongsberg Defence & Aerospace has struck a deal with Patria to supply several hundred PROTECTOR RS4 remote weapon stations for the German and Swedish CAVS 6×6 armoured vehicle programmes. The contract is worth about 140 million euros, with potential for follow-up orders. “This contract positions the RS4 as the standard weapon station configuration across the multinational CAVS fleet,” said executive vice president Kjetil Reiten Myhra. TradingView

Broker sentiment turned upbeat. Danske Bank’s Tomas Helgø gave a “hats off” nod to the strong quarterly results, saying it was “exactly what we want to see.” SB1 Markets’ Ole-Petter Sjøvold called the quarter “lights out” and pointed to a dividend that seemed bigger than expected. E24

Management, though, warned of a more challenging road ahead. CEO Geir Håøy called the split a move that will leave two firms grappling with “rising geopolitical tensions, trade conflicts and uncertainty.” His comments underscore the risk of erratic order flows and potential investor churn tied to the separation. Kongsberg

The annual report will drop on March 23, with the annual general meeting scheduled for April 13. First-quarter results are due out May 7.

Stock Market Today

  • Aquestive Therapeutics Reports Strong Q1 Results, Analysts Maintain 2026 Forecasts
    May 16, 2026, 8:17 PM EDT. Aquestive Therapeutics (NASDAQ:AQST) posted strong first-quarter results with revenues of $14 million, surpassing analyst expectations by 33%, and smaller-than-expected losses of $0.07 per share. Despite the upbeat quarter, analysts forecast a 3.6% revenue decline in 2026 to $48.4 million and a 15% decrease in losses to $0.47 per share. The consensus price target remains steady at $8.89, suggesting the stock is trading in line with expectations amid continuing losses. Revenue growth is expected to slow significantly compared to the past five years, lagging behind an 8% annual growth forecast for the wider industry. Investors face mixed views on valuation, with targets ranging from $6.00 to $11.00 per share.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Gold price rebounds after violent selloff as traders brace for more volatility
Previous Story

Gold price rebounds after violent selloff as traders brace for more volatility

Ford stock slips before market open as EV sales dive and Geely talks linger
Next Story

Ford stock slips before market open as EV sales dive and Geely talks linger

Go toTop